Pinealon Peptide UK: EDR Research, Mechanism and Study Data

Three amino acids. That is the whole of Pinealon. No elaborate folded structure, no long chain, no clever chemical modification bolted on to make it last longer. Just glutamic acid, aspartic acid and arginine, joined end to end. And yet this tiny molecule has spent more than two decades at the centre of one of the most unusual research programmes in peptide science, one built on the idea that very short peptides might reach inside a cell, find their way to its DNA and nudge which genes get switched on.

If that sounds too simple to be true, that is exactly why Pinealon is worth understanding properly. This guide walks through where it came from, what the published work has actually looked at, why researchers keep coming back to it alongside Epitalon, Semax and DSIP, and what to look for when sourcing it. Pinealon is sold by Crown Peptides strictly for laboratory research use only, and everything below is written for readers interested in the science.

What Is Pinealon, and Why Does Something So Small Get So Much Attention?

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg. In the scientific literature you will often see it written as EDR, which is simply the one-letter code for those three amino acids: E for glutamic acid, D for aspartic acid and R for arginine. Its molecular formula is C15H26N6O8 and its molecular weight sits at roughly 418 g/mol, which makes it one of the smallest biologically active peptides you will find on any research catalogue.

To put that in perspective, a peptide like BPC-157 is 15 amino acids long. Thymosin beta-4, the parent of TB-500, is 43. Insulin has 51. Pinealon has three. It is closer in size to a single sugar molecule than to most of the peptides people usually think of.

That size is the whole story. Large peptides generally act from the outside, docking onto a receptor on the cell surface and triggering a chain of signals inside. A molecule as small as Pinealon has other options. It may be able to cross membranes, pass into the cell interior and, according to the research group that developed it, reach the nucleus itself. That idea is what turns a three-amino-acid fragment into one of the more talked-about compounds in neuroscience-adjacent peptide research.

Where does the name come from?

The name points to the pineal gland, the small pine-cone-shaped structure deep in the brain best known for producing melatonin. That link is partly historical. Pinealon belongs to a family of short peptides developed by the same group that created Epitalon, which was designed from an extract of the pineal region. In practice, though, Pinealon’s research story is mostly about neurons in general, particularly cells in the cerebellum, hippocampus and cortex, rather than the pineal gland specifically. The name is a family resemblance more than a job description.

What does Pinealon do in research models?

Research has indicated that Pinealon may protect neurons in several ways, and the published findings fall into a few recurring themes: protection of neurons against oxidative stress, reduced cell death under stressful conditions, preservation of dendritic spines (the tiny connection points neurons use to talk to each other), and changes in the activity of genes linked to antioxidant defence and cell survival. Each of those is covered in more detail below, with the specific studies named.

The Soviet Military Programme That Started It All

To understand why anyone would bother studying a three-amino-acid peptide, you have to go back to the 1970s and a research project that began, of all places, inside the Soviet military medical system.

A young military doctor named Vladimir Khavinson, working at the Kirov Military Medical Academy in Leningrad, was part of a group tasked with finding ways to protect and restore the health of personnel exposed to extreme stress: radiation, hypoxia, long deployments, the kind of environments that grind the body down faster than normal ageing. His team’s approach was unusual. Rather than looking for a single drug aimed at a single target, they extracted mixtures of short peptides from specific animal organs and tested whether those extracts helped the matching organ in the recipient function better.

The logic was that each tissue might carry its own set of small regulatory peptides, and that supplying those signals could help ageing or damaged tissue behave more like young, healthy tissue. Khavinson called these compounds peptide bioregulators. The extracts that came out of this work, including Epithalamin from the pineal region and Cortexin from the brain’s cortex, went on to be registered as medicines in Russia.

From crude extracts to a precise sequence

Extracts have an obvious weakness: nobody knows exactly which molecule inside them is doing the work. So the next phase of the programme, which continued after Khavinson founded the Saint Petersburg Institute of Bioregulation and Gerontology in 1992, involved analysing the amino acid composition of each extract and designing short synthetic peptides that captured its core activity.

Epithalamin gave rise to Epitalon, the four-amino-acid sequence Ala-Glu-Asp-Gly. Cortexin, the brain extract, gave rise to Pinealon. By stripping the idea down to a precisely defined three-amino-acid chain, the group could make the compound synthetically, reproducibly and at high purity, which is exactly what modern laboratory research demands. That shift from animal extract to synthetic sequence is the reason Pinealon can be manufactured and verified by HPLC and mass spectrometry today.

A family of short peptides, not a one-off

Pinealon is one of a whole set of synthetic bioregulators to come out of the Saint Petersburg institute. Others include Vesugen (Lys-Glu-Asp, often written KED), linked in the group’s work to blood vessels, Testagen (Lys-Glu-Asp-Gly), and Bronchogen (Ala-Glu-Asp-Leu). You will see KED appear repeatedly alongside EDR in the research below, because the institute has often tested them side by side. That comparative design turns out to be useful: when one short peptide does something and a closely related one does not, it strengthens the case that the effect is specific to the sequence rather than a general property of any tiny peptide.

How Could a Three-Amino-Acid Peptide Talk to DNA?

This is the part most people find hardest to believe, so it is worth slowing down and taking it one step at a time.

Step one: getting inside the cell

Cells are wrapped in a fatty membrane that keeps most large molecules out. But cells also need to take in nutrients, including amino acids and very short peptides from digested protein, so they have dedicated transport proteins built for the job. Two families matter here. The PEPT transporters (such as PEPT1) move di- and tri-peptides across membranes, and the LAT transporters (LAT1 and LAT2) move amino acids.

In a computational study published in Biomolecules, Khavinson and colleagues modelled how 26 biologically active ultrashort peptides might fit into these transporters and compared them against thousands of random two- and three-amino-acid combinations (PMID: 36979488, PMC10046148). EDR was named among the most effective binders. The biologically active peptides consistently scored higher than random sequences, which gives a plausible route by which Pinealon could get into cells. It also helps explain why oral and capsule forms of related bioregulators exist in some markets, since PEPT1 is heavily expressed in the gut lining.

Step two: reaching the nucleus

Getting into the cell is one thing. Getting into the nucleus, where DNA lives, is another. Here the evidence is visual. In a study published in Biochemistry (Moscow), researchers attached a fluorescent label to Pinealon, Epitalon and Testagen, then incubated them with HeLa cells and watched where the glow ended up (PMID: 22117547). All three peptides produced marked fluorescence in the cytoplasm, the nucleus and even the nucleolus, the dense region inside the nucleus where ribosomes are assembled.

Step three: recognising particular DNA sequences

The same study went further. Using fluorescence quenching, a technique that measures how strongly one molecule interferes with the light given off by another, the team showed that different short peptides interacted differently with different DNA sequences. Pinealon, along with Epitalon and Testagen, appeared to prefer sequences containing CAG repeats. The peptides also seemed sensitive to whether cytosine bases were methylated, which matters because methylation is one of the main ways cells mark genes as on or off.

That is a striking claim, and it is the foundation of the idea that Pinealon acts as an epigenetic regulator: something that influences which genes are expressed without changing the DNA code itself.

Step four: which genes?

Later work used molecular docking, computer modelling of how a molecule fits against another, to look for where EDR might bind in the promoter regions of genes. Promoters are the stretches of DNA just before a gene that control whether it gets read. In the 2021 Pharmaceuticals paper covered in detail below, the team reported predicted EDR binding sites in the promoters of genes including CASP3 (caspase-3, a key driver of programmed cell death), SOD2 (a major mitochondrial antioxidant enzyme), GAP43 (involved in nerve growth and repair), APOE, PPARA and PPARG. Every one of those genes has a known role in how neurons cope with stress and ageing.

The full DNA-interaction hypothesis, and why it is both fascinating and still being worked out, gets its own deep dive in our companion article, Pinealon: the three-amino-acid peptide that talks directly to neuronal DNA.

What the Published Research Has Actually Found

So much for the theory. The more interesting question is what happens when Pinealon is put into cells and animal models and measured. The body of work is concentrated in a handful of groups, mostly in Saint Petersburg and Moscow, and it spans cell culture, rodent studies and a smaller set of observational human reports. Here are the studies that matter most.

Protecting neurons from oxidative stress

The most widely cited Pinealon paper is a 2011 study in Rejuvenation Research by Khavinson, Boldyrev and colleagues (PMID: 21978084). The team exposed three different cell types to oxidative stress: cerebellar granule cells (neurons from the part of the brain involved in coordination), neutrophils (a type of white blood cell) and PC12 cells (a cell line widely used as a stand-in for neurons).

Pinealon produced a dose-dependent reduction in the build-up of reactive oxygen species, the unstable molecules that damage proteins, fats and DNA when they accumulate. It also reduced necrotic cell death, measured using a standard dye test that only stains cells whose membranes have broken down.

Here is where it gets interesting. The antioxidant effect levelled off at relatively low concentrations. But at higher concentrations, Pinealon kept changing something else: the cell cycle, the ordered process cells go through to grow and divide. It also altered the timing of ERK 1/2 activation, a signalling pathway central to cell survival. The authors’ conclusion was that Pinealon was doing more than mopping up free radicals. The pattern suggested it was interacting directly with the cell’s genetic machinery, which fits neatly with the DNA-binding work above.

Protecting offspring in a prenatal stress model

A year later, a study in the International Journal of Clinical and Experimental Medicine took Pinealon into a living animal model (PMID: 22567179, PMC3342713). Pregnant rats were fed a high-methionine diet to raise their homocysteine levels, a condition called hyperhomocysteinemia that is known to impair brain development in offspring.

When the pregnant rats were given Pinealon, their offspring showed significantly better spatial orientation and learning ability than offspring from untreated high-homocysteine mothers. When the researchers isolated neurons from the offspring’s cerebellum, those cells accumulated fewer reactive oxygen species and showed fewer necrotic deaths. The authors described this as confirmation in a living model of the neuroprotective effects they had previously seen in cell culture.

Restoring dendritic spines in Alzheimer’s models

Perhaps the most eye-catching Pinealon result involves dendritic spines. These are tiny protrusions on neurons where most excitatory connections form. The mature, stable type are called mushroom spines, because under a microscope that is exactly what they look like. They are thought to be the physical basis of long-term memory, and their loss is one of the earliest changes seen in Alzheimer’s disease.

In a 2017 study in the Bulletin of Experimental Biology and Medicine, researchers grew mouse hippocampal neurons and exposed them to amyloid, the protein that clumps into plaques in Alzheimer’s disease (PMID: 28853087). Amyloid exposure cut the number of mushroom spines. Adding EDR at 200 ng/ml increased mushroom spine numbers by 71%, bringing them back to normal levels. The related tripeptide KED, tested under the same conditions, produced a 20% increase. That gap between two very similar molecules is exactly the kind of sequence-specific result that makes the research group’s case stronger.

Taking it into a mouse model

The team followed up in 2021 with a study published in Pharmaceuticals (PMID: 34071923, PMC8227791). This time they used 5xFAD mice, a strain engineered to develop Alzheimer’s-like pathology rapidly. Both EDR and KED prevented the loss of dendritic spines in neurons from these mice. The same paper contained the molecular docking work identifying predicted EDR binding sites in genes such as CASP3, SOD2, GAP43 and APOE, tying the physical result back to the proposed epigenetic mechanism.

Huntington’s disease models too

According to a 2020 review in Molecules by Khavinson and colleagues (PMID: 33396470, PMC7795577), EDR has also been shown to interfere with the elimination of dendritic spines in neuronal cultures derived from Huntington’s disease mouse models, not only Alzheimer’s ones. The same review summarises the wider picture: EDR has been linked to changes in the MAPK/ERK signalling pathway, reduced synthesis of pro-apoptotic proteins such as caspase-3 and p53, increased activity of antioxidant enzymes such as SOD2 and GPX1, and effects on serotonin and calmodulin.

Ageing human neurons in a dish

The newest line of work is arguably the most elegant. In a 2024 study in the International Journal of Molecular Sciences, a team from the Institute of Cytology in Saint Petersburg took skin fibroblasts from elderly human donors and reprogrammed them directly into cortical neurons (PMID: 39518916, PMC11546785).

Why does that matter? Because neurons made this way keep many of the age-related marks of the donor. Unlike neurons made from stem cells, which are effectively reset to a young state, these induced neurons behave like old neurons. That makes them one of the best available models for studying neuronal ageing in human cells.

EDR, KED and Epitalon (AEDG) were each tested. All three promoted dendritic branching, increasing both the number of primary dendrites and their total length. EDR stood out for one additional finding: it reduced oxidative DNA damage in the neurons derived from elderly donors. Mitochondrial and lysosomal activity and levels of the ageing marker p16 were not changed by the tripeptides, which is useful context in its own right because it shows the effect was specific rather than a blanket shift in every measure.

Hypoxia and ageing rat studies

A cluster of papers from Mendzheritsky and colleagues, published in the Russian journal Advances in Gerontology, compared Pinealon with its parent extract Cortexin in older rats exposed to hypoxia (low oxygen), hypothermia and carotid artery occlusion. Across these studies, the group looked at behaviour, learning in navigation tasks, blood cytokine levels and caspase-3 activity in brain tissue. These papers are largely published in Russian, but their abstracts consistently report protective effects of the short peptides on caspase-3 activity and behaviour in older animals.

What about human data?

There is a small body of human observational work, again mostly in Advances in Gerontology, looking at short peptide bioregulators in older adults and in occupational groups under chronic stress, such as locomotive crews and long-distance truck drivers. The 2020 Molecules review reports that EDR has been shown to improve memory issues in elderly patients in this work. These studies are small, open-label and published in Russian-language journals, so they sit at the preliminary end of the evidence scale. They are best read as a signal that has encouraged further laboratory work rather than as settled findings.

Pinealon Research Peptide

HPLC and MS verified · batch certificate published · dispatched from the UK before 2pm

from£34.99View Pinealon Research Peptide

Pinealon vs Epitalon: Siblings With Different Jobs

This is one of the most searched questions about Pinealon, and for good reason. The two peptides come from the same institute, the same founder and the same bioregulator philosophy. They are often studied in the same experiments. But they are aimed at different systems.

Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract Epithalamin. Its research profile centres on telomerase activity, telomere length, melatonin rhythms and whole-body ageing markers. It is, in short, the longevity peptide of the pair.

Pinealon, derived from the brain extract Cortexin, is the neuron specialist: research has indicated it may reduce oxidative stress in brain cells, preserve dendritic spines, improve learning in animal models and protect ageing human neurons from oxidative DNA damage. It is the brain peptide of the pair.

That is why researchers interested in ageing often look at the two together. One addresses the systemic clock, the other the neurons that clock is ticking inside. The 2024 induced-neuron study above is a good example of the pair being tested head to head, with both promoting dendrite growth but EDR additionally reducing oxidative DNA damage. If Epitalon is on your list too, our Epitalon research guide covers its telomerase work in depth.

Is there a Pinealon and Epitalon stack?

You will see “Pinealon Epitalon stack” come up a lot in search, and it reflects how often the two are discussed together. In the published literature they have been studied in parallel within the same experiments rather than as a formal combined preparation. For laboratory work the practical point is simple: they are separate compounds with separate identities, and each should come with its own batch-specific certificate of analysis.

How Pinealon Compares With Semax, Selank and DSIP

Search data shows that people researching Pinealon very often compare it with three other compounds: Semax, Selank and DSIP. The comparisons make sense, because all four turn up in neuroscience-focused research. But they work in very different ways.

Pinealon vs Semax

Semax is a seven-amino-acid peptide based on a fragment of ACTH (adrenocorticotropic hormone), developed at the Institute of Molecular Genetics in Moscow. Research has shown it can raise brain-derived neurotrophic factor (BDNF) in the rat hippocampus, and it has been studied for attention and neuroprotection in models of stroke. Semax works largely through signalling cascades triggered from the outside of the cell. Pinealon’s proposed route is the opposite: small enough to go inside and act at the level of gene expression. Both are Russian in origin and both are neuroprotection-focused, but they are asking different questions.

Pinealon vs Selank

Selank is a synthetic analogue of tuftsin, a naturally occurring immune peptide, with a short stabilising sequence added. Its research profile is focused on the GABA system, anxiety-related behaviour in animal models and immune modulation. Where research indicates Pinealon may protect the structure of neurons, Selank’s research points to effects on mood-related signalling. Researchers interested in the Semax and Selank pairing can find both in our Semax 5mg + Selank 5mg (Blend), and the differences are laid out in Semax vs Selank: two peptides, two different mechanisms.

Pinealon vs DSIP for sleep research

“Pinealon vs DSIP for sleep” is a surprisingly common search. It probably stems from the pineal name, since the pineal gland produces melatonin. But Pinealon’s published research is not really about sleep. DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated in 1977 from the blood of rabbits in induced sleep, and its research is directly tied to slow-wave sleep and stress hormone regulation. If sleep architecture is the research question, DSIP is the more directly relevant compound. If neuronal resilience is the question, Pinealon is. Our DSIP research guide goes into its unusual discovery story.

The Technical Breakdown: Pinealon Structure and Chemistry

This section is for readers who want the chemistry in more detail. If you only want the big picture, you can skip ahead without missing anything important.

Sequence and charge

Pinealon’s sequence, written from the N-terminus (the start of the chain) to the C-terminus (the end), is H-Glu-Asp-Arg-OH. Two of its three residues, glutamic acid and aspartic acid, carry negatively charged side chains at physiological pH. The third, arginine, carries a strongly positive charge. The result is a small molecule with a negatively charged front end and a positively charged tail.

That charge pattern is not incidental. The 2023 transporter modelling study found that peptides with negatively charged Asp or Glu residues at the N-terminus and neutral or positive residues at the C-terminus were among the most effective ligands for LAT1, LAT2 and PEPT1. Pinealon fits that profile precisely. The positively charged arginine is also relevant to the DNA-binding hypothesis, since DNA’s phosphate backbone is negatively charged and arginine residues are a classic feature of DNA-binding proteins such as histones.

Why ions matter to the DNA interaction

A 2019 study in the Journal of Physical Chemistry B from the physics faculty at Saint Petersburg State University used spectroscopy, NMR and molecular dynamics to watch EDR and DNA together (PMID: 30762356). The team reported that EDR can partly slip into the major groove of the DNA double helix and interact with specific atoms on guanine bases. Magnesium ions helped the interaction along by screening the negative charge on DNA’s phosphate backbone.

Stability considerations

As a free tripeptide without modified ends, Pinealon is susceptible to breakdown by peptidases in biological fluids, which is typical of very short peptides. In lyophilised (freeze-dried) powder form, kept cold, dry and away from light, it is stable. Once reconstituted, it should be kept refrigerated and used within the timeframe appropriate to the diluent. Our guides to peptide reconstitution and how long peptides last cover the practical detail, and our storage information page summarises the essentials.

Concentrations used in published studies

For researchers planning cell work, the published concentrations give useful reference points. The 2017 hippocampal neuron study used EDR at 200 ng/ml. The 2011 Rejuvenation Research study reported dose-dependent effects, with the antioxidant response saturating at lower concentrations than the cell cycle effects. When converting a vial’s contents into a working concentration, precision matters with a compound this light, because a small weighing or dilution error is proportionally large. The Crown Peptides peptide calculator and our explainer on mg vs mcg are built for exactly that job.

Why Purity Matters More Than Usual for a Tripeptide

It is tempting to assume that a peptide with only three amino acids is too simple to go wrong. In one sense that is true: short sequences are easier to synthesise than long ones. But short peptides bring their own quality challenges, and they are worth understanding before you buy.

The first is that impurities are proportionally significant. In a three-residue chain, a deletion sequence (where one amino acid failed to couple during synthesis) is not a slightly shorter version of the target. It is a two-amino-acid peptide, a completely different molecule. Glu-Asp, Asp-Arg and Glu-Arg are all plausible side products, and some dipeptides have biological activity of their own. The transporter study above specifically named DR and ED among biologically active ultrashort peptides. For research built on the idea that sequence specificity matters, a clean product is not a nice-to-have.

The second is that the whole scientific case for Pinealon rests on sequence-specific effects, the finding that EDR does something that KED, or a random tripeptide, does not. If your material is contaminated with related short peptides, you cannot cleanly attribute an effect to EDR.

What Crown Peptides checks on every batch

Every batch of Pinealon 10mg Research Peptide is supplied with a batch-specific certificate of analysis. High-performance liquid chromatography (HPLC) confirms purity by separating the target molecule from any related impurities and measuring each as a proportion of the total. Mass spectrometry confirms identity by measuring the molecular mass, which for Pinealon should correspond to roughly 418 Da. Together, those two tests answer the two questions that matter: is it the right molecule, and how much of the vial is that molecule?

You can view published certificates on our Lab Reports page, and if you want to understand exactly what each section of a certificate means, our guide on how to read a peptide certificate of analysis walks through it line by line. For a broader look at how testing works in the UK research market, see peptide testing UK.

Handling on arrival

Pinealon arrives as a lyophilised powder. Kept in the freezer or fridge, sealed and protected from moisture, it holds its integrity well. For reconstitution, most researchers use Bacteriostatic Water, which contains 0.9% benzyl alcohol to inhibit microbial growth in multi-use vials. Our bacteriostatic water guide explains when it is the right choice.

Related Compounds Worth Knowing About

Pinealon rarely appears in the literature on its own. It sits within a network of compounds studied for neuronal health, cellular ageing and oxidative stress. If you are building a research programme around Pinealon, these are the neighbours most likely to come up.

Epitalon

The closest relative. Same institute, same bioregulator family, same fluorescence studies showing entry into the nucleus. Epitalon is the systemic ageing counterpart to Pinealon’s neuronal focus, and the two were tested side by side in the 2024 induced-neuron ageing study. For a comparison with another longevity compound, see Epitalon vs NAD+.

Semax and Selank

The two Russian-developed neuropeptides most often mentioned in the same breath as Pinealon. Semax focuses on BDNF and neuroprotection after ischaemia, while Selank focuses on GABA-related signalling. Both are available individually and together in the Semax 5mg + Selank 5mg (Blend). Their individual research stories are covered in our Semax guide and Selank guide.

DSIP

The compound to look at if sleep is the actual research question. DSIP has a direct research connection to slow-wave sleep that Pinealon does not.

NAD+ and SS-31

If Pinealon’s antioxidant and neuronal ageing findings interest you, the mitochondrial side of the story is covered by NAD+, the coenzyme at the centre of cellular energy and DNA repair research, and SS-31, a mitochondria-targeted peptide studied for its protection of the inner mitochondrial membrane. Interestingly, EDR did not change mitochondrial activity in the 2024 induced-neuron study, which makes these compounds complementary rather than overlapping.

Glutathione

Pinealon’s research repeatedly touches on oxidative stress and antioxidant enzymes such as SOD2 and GPX1. Glutathione, the tripeptide often described as the body’s master antioxidant, is a natural point of comparison: another three-amino-acid molecule, but one that neutralises oxidants directly rather than, as proposed for Pinealon, influencing the genes that make antioxidant enzymes. Our glutathione article explains the chemistry.

For the full range, browse the neurocognitive research peptides and ageing and cellular research peptides categories.

Common Questions About Pinealon

What does EDR stand for?

EDR is the one-letter amino acid code for Pinealon’s sequence: E for glutamic acid, D for aspartic acid and R for arginine. Research papers use EDR and Pinealon interchangeably, so it is worth searching both terms when reading the literature.

Is Pinealon related to Cortexin?

Yes. Cortexin is a complex of polypeptides extracted from the brain cortex of young cattle and pigs, developed in the same Soviet and Russian bioregulator programme. Pinealon was designed as a short synthetic peptide capturing the activity of that extract, and several rat studies have compared the two directly.

Does Pinealon cross the blood-brain barrier?

Its small size and the transporter modelling work make brain entry plausible, and the 2012 prenatal study and the Mendzheritsky rat studies reported effects on brain tissue after the peptide was given outside the brain. Direct measurement of how much Pinealon reaches the brain in living animals remains an open research question, which is part of what makes it an interesting compound to study.

Why is Pinealon sold as a 10mg vial?

Because published cell work uses very low concentrations, such as 200 ng/ml, a 10mg vial goes a long way in a laboratory setting. Getting the arithmetic right is the main practical challenge, which is why our peptide calculation guide is worth bookmarking.

Is Pinealon legal to buy in the UK?

Pinealon is not a controlled substance in the UK and can be bought for laboratory research. For a full explanation of how UK law treats research peptides, see are peptides legal in the UK.

The Smallest Idea in Peptide Science Might Be One of the Biggest

Most of the peptides that dominate research conversations work by being big enough to grip a receptor. Pinealon is interesting for the opposite reason. It is small enough that it might skip the receptor entirely, slip into the cell, reach the nucleus and interact with the machinery that decides which genes get read.

That idea began in a Cold War military lab trying to keep soldiers resilient under extreme stress. Half a century later it has produced a trail of studies showing reduced oxidative damage in neurons, restored dendritic spines in Alzheimer’s and Huntington’s models, better learning in rats exposed to prenatal stress, and more branched, less damaged neurons grown from the skin cells of elderly people. The work is concentrated in a small number of groups and there is plenty still to be mapped out, particularly around exactly how much Pinealon reaches the brain and which of its predicted gene targets matter most. That is precisely what makes it an exciting compound to work with right now: the open questions are well defined, the tools to answer them exist, and the molecule itself is simple enough to make and verify to a very high standard.

If you are ready to explore those questions in your own work, start with material you can trust. Pinealon 10mg Research Peptide from Crown Peptides comes with a batch-specific certificate confirming its identity by mass spectrometry and its purity by HPLC, dispatched from the UK.